It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory committee ...

Good afternoon, everyone. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Alex Morrison. I'm an associate on JPM's health care team. Today, it's my pleasure to introduce Lexicon ...

THE WOODLANDS, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a business and pipeline update at the 44th Annual J.P. Morgan Healthcare Conference ...

SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista on track for NDA ...

Get the detailed quarterly/annual income statement for Lexicon Pharmaceuticals, Inc. (LXRX). Find out the revenue, expenses and profit or loss over the last fiscal year.

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

This repository contains the official PyTorch implementation of the paper "Lexicon3D: Probing Visual Foundation Models for Complex 3D Scene Understanding". The paper is available on arXiv. The project ...